Ypsomed Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a YPHDF research report →
Price Chart
About the company
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices.
- CEO
- Simon Michel
- IPO
- 2022
- Employees
- 2,025
- HQ
- Burgdorf, BE, CH
Get TickerSpark's AI analysis on YPHDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $5.74B
- P/E
- 34.74
- Fwd P/E
- 26.75
- PEG
- 0.35
- P/S
- 8.40
- P/B
- 7.25
- EV/EBITDA
- 20.11
- Div Yield
- 1.00%
- Gross Margin
- 46.98%
- Op Margin
- 30.43%
- Net Margin
- 24.55%
- ROE
- 21.82%
- ROIC
- 13.82%
Latest fiscal year · YoY change
- Revenue
- $730.98M-2.4%
- Gross Profit
- $314.61M+7.7%
- Op Income
- $246.07M
- Net Income
- $221.93M+153.6%
- EPS
- $16.31+154.4%
- OCF Growth
- +107.0%
- FCF Growth
- +87.3%
- 52W High
- $501.00
- 52W Low
- $354.92
- 50D MA
- $437.84
- 200D MA
- $411.44
- Beta
- 0.89
- RSI (14)
- 20
- Avg Volume
- 1
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ypsomed posted a strong first half, lifted full-year guidance, and said growth is being driven by autoinjectors, new wins, and capacity expansion while margins remain unusually high.· November 11, 2026
- Sales reached CHF 318 million, with Delivery Systems growing 17.5% and commercial sales rising from about CHF 200 million to CHF 243 million.
- EBIT came in at CHF 102 million, implying a 35.7% margin, helped by a favorable mix and strong autoinjector growth.
- Full-year guidance was raised to 13% to 16% sales growth and CHF 220 million to CHF 240 million of EBIT.
- Management said Ypsomed won 30 new projects and 10 new customers in the half, and now serves 130 customers across close to 300 clinical and commercial programs.
- Capex remains elevated, with CHF 130 million invested in fixed assets in the half and full-year fixed asset investments expected to be close to CHF 300 million.
Ypsomed reported CHF 318 million of sales in the first half. Delivery Systems sales grew 17.5%, with commercial sales increasing from roughly CHF 200 million to CHF 243 million and project revenue rising from CHF 43 million to CHF 44 million. EBIT was CHF 102 million, representing a 35.7% margin. Cash flow from operations was close to CHF 120 million, while free cash flow was slightly negative because investing cash outflows remained larger. The company raised full-year guidance to sales growth of 13% to 16% from 12% to 15%, and EBIT of CHF 220 million to CHF 240 million from CHF 210 million to CHF 230 million. Midterm guidance was reaffirmed at CHF 0.9 billion to CHF 1.1 billion of sales and CHF 280 million to CHF 340 million of EBIT by business year 2029/2030; management also expects business-year 2027/2028 to be free-cash-flow positive.
Simon Michel framed the half as a clear proof point for Ypsomed’s transformation into a pure-play self-injection specialist and said the company is benefiting from structural demand in home care, biologics, biosimilars, and GLP-1s. He emphasized that autoinjectors are the current growth engine, while the platform breadth lets Ypsomed serve both pens and autoinjectors across multiple therapeutic areas. His tone was confident and upbeat, but he also noted that the company is managing a large capacity build-out, pricing discipline, and long-cycle product transitions.
Samuel Kunzli highlighted that the first half delivered CHF 318 million of sales, CHF 102 million of EBIT, and a 35.7% EBIT margin, while operating cash flow was close to CHF 120 million. He said the company invested CHF 130 million in fixed assets, is close to the peak of its capex cycle, and expects fixed asset investments for the full year to be close to CHF 300 million. He also pointed to a solid balance sheet, with EBITDA over the last 12 months north of CHF 300 million and current debt around CHF 300 million, giving a net debt-to-EBITDA ratio of around 1.0. He reiterated that guidance was raised and said the company expects to turn free-cash-flow positive in business year 2027/2028.
Analysts focused on the Sanofi wind-down, margin durability, capacity reservation, the GLP-1 mix, China strategy, and what to expect from YpsoFit and M&A. Management said the Sanofi phase-out will have only a minor second-half impact and that the effect sits in the Other segment rather than Delivery Systems, while Other EBIT should remain slightly negative in the second half. On margins, management said the current high level reflects strong autoinjector mix and pricing, but margins should gradually ease over time as Ypsomed shares economies of scale with customers; they still expect to stay above 30%. On China, Ypsomed said it will compete above the domestic low-end market with its current portfolio, while also considering a low-cost internal platform, a Chinese contract manufacturer, or a local acquisition for the value segment.
The call showed strong underlying demand, with 30 new project wins, 10 new customers, and broad traction outside GLP-1s, especially in autoimmune and other specialty therapies. Ypsomed also delivered unusually strong profitability despite major capacity investments, and management raised both sales and EBIT guidance for the year. The company says it has a long runway from its pipeline, new sites, and product launches, including larger-volume autoinjectors and future benefits from YpsoFit.
Management repeatedly signaled that margins should gradually come down from the current level because of ramp-up costs and volume-based pricing, even if they remain above 30%. Free cash flow is still slightly negative as capex stays near peak, and the company is investing heavily across Switzerland, Germany, China, and the U.S. The Other segment remains a drag as contract manufacturing phases out, and management also noted some uncertainty around China pricing, client migration to new materials, and the timing/impact of M&A.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 26.7%
- Shares Outstanding
- 13.15M
- Float Shares
- 3.51M
Our YPHDF coverage
Recent articles, reports, and earnings notes.
No research on YPHDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate YPHDF report →Ypsomed Holding AG (YPHDF) Q2 2027 Earnings Call Transcript
seekingalpha.com · Nov 11
Ypsomed Holding AG (YPHDF) Q4 2026 Earnings Call Transcript
seekingalpha.com · May 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.